{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:29:22Z","timestamp":1780568962705,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007423","name":"Lyda Hill Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007423","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stiefel Oropharyngeal Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40273-018-0691-9","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T17:24:41Z","timestamp":1531934681000},"page":"1355-1365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients"],"prefix":"10.1007","volume":"36","author":[{"given":"Kristina R.","family":"Dahlstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyaw","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeena","family":"Shelal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois M.","family":"Ramondetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lairson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"691_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/AOG.0b013e31821a0f4d","volume":"118","author":"LS Massad","year":"2011","unstructured":"Massad LS, Xie X, Darragh T, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol. 2011;118:831\u20139.","journal-title":"Obstet Gynecol"},{"key":"691_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1086\/597071","volume":"199","author":"SM Garland","year":"2009","unstructured":"Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805\u201314.","journal-title":"J Infect Dis"},{"key":"691_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1086\/427557","volume":"191","author":"RL Winer","year":"2005","unstructured":"Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191:731\u20138.","journal-title":"J Infect Dis"},{"key":"691_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/OLQ.0b013e3181632d61","volume":"35","author":"TH Dinh","year":"2008","unstructured":"Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, National Health and Nutrition Examination Survey, 1999\u20132004. Sex Transm Dis. 2008;35:357\u201360.","journal-title":"Sex Transm Dis"},{"key":"691_CR5","volume-title":"Sexually transmitted disease surveillance 2016","author":"Centers for Disease Control and Prevention","year":"2017","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2016. Atlanta: US Department of Health and Human Services; 2017."},{"key":"691_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/OLQ.0b013e3182953ce0","volume":"40","author":"DR Camenga","year":"2013","unstructured":"Camenga DR, Dunne EF, Desai MM, et al. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis. 2013;40:534\u20138.","journal-title":"Sex Transm Dis"},{"key":"691_CR7","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","volume":"29","author":"HW Chesson","year":"2011","unstructured":"Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443\u201350.","journal-title":"Vaccine."},{"issue":"Suppl 8","key":"691_CR8","doi-asserted-by":"publisher","first-page":"S849","DOI":"10.1093\/cid\/civ813","volume":"61","author":"IU Park","year":"2015","unstructured":"Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S849\u201355.","journal-title":"Clin Infect Dis"},{"key":"691_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11591170-000000000-00000","volume":"30","author":"AJ Raymakers","year":"2012","unstructured":"Raymakers AJ, Sadatsafavi M, Marra F, Marra CA. Economic and humanistic burden of external genital warts. Pharmacoeconomics. 2012;30:1\u201316.","journal-title":"Pharmacoeconomics."},{"key":"691_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/sti.2008.030999","volume":"85","author":"F Marra","year":"2009","unstructured":"Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2009;85:111\u20135.","journal-title":"Sex Transm Infect."},{"key":"691_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6404a1","volume":"64","author":"KA Workowski","year":"2015","unstructured":"Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1\u2013137.","journal-title":"MMWR Recomm Rep."},{"key":"691_CR12","first-page":"1","volume":"63","author":"LE Markowitz","year":"2014","unstructured":"Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1\u201330.","journal-title":"MMWR Recomm Rep."},{"key":"691_CR13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.15585\/mmwr.mm6633a2","volume":"66","author":"TY Walker","year":"2017","unstructured":"Walker TY, Elam-Evans LD, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317\u00a0years\u2014United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:874\u201382.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"691_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jamapediatrics.2013.2752","volume":"168","author":"DM Holman","year":"2014","unstructured":"Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 2014;168:76\u201382.","journal-title":"JAMA Pediatr."},{"key":"691_CR15","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","volume":"28","author":"EH Elbasha","year":"2010","unstructured":"Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858\u201367.","journal-title":"Vaccine."},{"key":"691_CR16","doi-asserted-by":"publisher","first-page":"djv282","DOI":"10.1093\/jnci\/djv282","volume":"108","author":"M Brisson","year":"2015","unstructured":"Brisson M, Laprise JF, Chesson HW, et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 2015;108:djv282. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv282\n                    \n                  .","journal-title":"J Natl Cancer Inst."},{"key":"691_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40273-016-0407-y","volume":"34","author":"J Pink","year":"2016","unstructured":"Pink J, Parker B, Petrou S. Cost effectiveness of HPV vaccination: a systematic review of modelling approaches. Pharmacoeconomics. 2016;34:847\u201361.","journal-title":"Pharmacoeconomics."},{"key":"691_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ygyno.2017.02.011","volume":"145","author":"DR Lairson","year":"2017","unstructured":"Lairson DR, Fu S, Chan W, Xu L, Shelal Z, Ramondetta L. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol Oncol. 2017;145:108\u201313.","journal-title":"Gynecol Oncol"},{"key":"691_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1758-3284-4-15","volume":"4","author":"JJ Jacobson","year":"2012","unstructured":"Jacobson JJ, Epstein JB, Eichmiller FC, et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid. Head Neck Oncol. 2012;4:15 (3284-4-15).","journal-title":"Head Neck Oncol."},{"key":"691_CR20","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1097\/MLR.0b013e3181a4f482","volume":"47","author":"KR Yabroff","year":"2009","unstructured":"Yabroff KR, Warren JL, Schrag D, et al. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care. 2009;47:S56\u201363.","journal-title":"Med Care"},{"key":"691_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40273-016-0438-4","volume":"34","author":"TJ Mattingly","year":"2016","unstructured":"Mattingly TJ, Mullins CD, Onukwugha E. Publication of cost-of-illness studies: does methodological complexity matter? Pharmacoeconomics. 2016;34:1067\u201370.","journal-title":"Pharmacoeconomics."},{"key":"691_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-015-0325-4","volume":"34","author":"E Onukwugha","year":"2016","unstructured":"Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. Pharmacoeconomics. 2016;34:43\u201358.","journal-title":"Pharmacoeconomics."},{"key":"691_CR23","first-page":"251","volume":"77","author":"WG Manning","year":"1987","unstructured":"Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77:251\u201377.","journal-title":"Am Econ Rev."},{"key":"691_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2307\/2529981","volume":"36","author":"DB Rubin","year":"1980","unstructured":"Rubin DB. Bias reduction using Mahalanobis-metric matching. Biometrics. 1980;36:293\u20138.","journal-title":"Biometrics"},{"key":"691_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.6004","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33:1057\u201369.","journal-title":"Stat Med"},{"key":"691_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0895-4356(96)00271-5","volume":"49","author":"W D\u2019Hoore","year":"1996","unstructured":"D\u2019Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49:1429\u201333.","journal-title":"J Clin Epidemiol"},{"key":"691_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00005650-198905000-00009","volume":"27","author":"ML Ashcraft","year":"1989","unstructured":"Ashcraft ML, Fries BE, Nerenz DR, et al. A psychiatric patient classification system. An alternative to diagnosis-related groups. Med Care. 1989;27:543\u201357.","journal-title":"Med Care"},{"key":"691_CR28","unstructured":"Bureau of Labor Statistics.\u00a0Consumer Price Index-Medical Care. \n                    http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu\n                    \n                  . Accessed 10 Oct 2017."},{"key":"691_CR29","first-page":"96","volume-title":"Economic Evaluation in Clinical Trials","author":"Dr. Henry A. Glick","year":"2014","unstructured":"Glick H, Doshi J, Sonnad S, Polsky D. Analyzing cost. In: Anonymous economic evaluation in clinical trials. New York: Oxford University Press; 2014. pp. 96."},{"key":"691_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0304-4076(81)90071-3","volume":"16","author":"H Akaike","year":"1981","unstructured":"Akaike H. Likelihood of a model and information criteria. J Econom. 1981;16:3\u201314.","journal-title":"J Econom."},{"key":"691_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2334-8-76","volume":"8","author":"P Hillemanns","year":"2008","unstructured":"Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76 (2334-8-76).","journal-title":"BMC Infect Dis."},{"key":"691_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/1471-2334-13-470","volume":"13","author":"MM Gianino","year":"2013","unstructured":"Gianino MM, Delmonte S, Lovato E, et al. A retrospective analysis of the costs and management of genital warts in Italy. BMC Infect Dis. 2013;13:470 (2334-13-470).","journal-title":"BMC Infect Dis."},{"key":"691_CR33","doi-asserted-by":"publisher","first-page":"e0139062","DOI":"10.1371\/journal.pone.0139062","volume":"10","author":"E Ostensson","year":"2015","unstructured":"Ostensson E, Froberg M, Leval A, et al. Cost of preventing, managing, and treating human papillomavirus (HPV)-related diseases in Sweden before the introduction of quadrivalent HPV vaccination. PLoS One. 2015;10:e0139062.","journal-title":"PLoS One"},{"key":"691_CR34","doi-asserted-by":"publisher","first-page":"e0177762","DOI":"10.1371\/journal.pone.0177762","volume":"12","author":"TG Ginindza","year":"2017","unstructured":"Ginindza TG, Sartorius B, Dlamini X, Ostensson E. Cost analysis of human papillomavirus-related cervical diseases and genital warts in Swaziland. PLoS One. 2017;12:e0177762.","journal-title":"PLoS One"},{"key":"691_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1377\/hlthaff.22.3.89","volume":"22","author":"GF Anderson","year":"2003","unstructured":"Anderson GF, Reinhardt UE, Hussey PS, Petrosyan V. It\u2019s the prices, stupid: why the United States is so different from other countries. Health Aff (Millwood). 2003;22:89\u2013105.","journal-title":"Health Aff (Millwood)."},{"key":"691_CR36","doi-asserted-by":"publisher","first-page":"500.e1","DOI":"10.1016\/j.ajog.2008.03.064","volume":"198","author":"D Hu","year":"2008","unstructured":"Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198:500.e1\u20137.","journal-title":"Am J Obstet Gynecol."},{"key":"691_CR37","doi-asserted-by":"publisher","first-page":"b3884","DOI":"10.1136\/bmj.b3884","volume":"339","author":"JJ Kim","year":"2009","unstructured":"Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.","journal-title":"BMJ"},{"key":"691_CR38","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1086\/375074","volume":"36","author":"RP Insinga","year":"2003","unstructured":"Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397\u2013403.","journal-title":"Clin Infect Dis"},{"key":"691_CR39","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1185\/03007990903136378","volume":"25","author":"T Hoy","year":"2009","unstructured":"Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin. 2009;25:2343\u201351.","journal-title":"Curr Med Res Opin"},{"key":"691_CR40","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928\u201343.","journal-title":"N Engl J Med"},{"key":"691_CR41","doi-asserted-by":"publisher","first-page":"c3493","DOI":"10.1136\/bmj.c3493","volume":"341","author":"FUTURE I\/II Study Group, Dillner J, Kjaer SK, et al","year":"2010","unstructured":"FUTURE I\/II Study Group, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.","journal-title":"BMJ"},{"key":"691_CR42","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","volume":"2","author":"SK Kjaer","year":"2009","unstructured":"Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa). 2009;2:868\u201378.","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"691_CR43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Munoz","year":"2010","unstructured":"Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102:325\u201339.","journal-title":"J Natl Cancer Inst"},{"key":"691_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","volume":"11","author":"B Donovan","year":"2011","unstructured":"Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11:39\u201344.","journal-title":"Lancet Infect Dis."},{"key":"691_CR45","doi-asserted-by":"publisher","first-page":"f2032","DOI":"10.1136\/bmj.f2032","volume":"346","author":"H Ali","year":"2013","unstructured":"Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.","journal-title":"BMJ"},{"key":"691_CR46","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.2105\/AJPH.2012.301182","volume":"103","author":"EW Flagg","year":"2013","unstructured":"Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003\u20132010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103:1428\u201335.","journal-title":"Am J Public Health"},{"key":"691_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12879-016-1347-z","volume":"16","author":"MA Smith","year":"2016","unstructured":"Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis. 2016;16:52 (016-1347-z).","journal-title":"BMC Infect Dis."},{"key":"691_CR48","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/OLQ.0000000000000418","volume":"43","author":"S Bollerup","year":"2016","unstructured":"Bollerup S, Baldur-Felskov B, Blomberg M, Baandrup L, Dehlendorff C, Kjaer SK. Significant reduction in the incidence of genital warts in young men 5\u00a0years into the Danish human papillomavirus vaccination program for girls and women. Sex Transm Dis. 2016;43:238\u201342.","journal-title":"Sex Transm Dis"},{"key":"691_CR49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/OLQ.0b013e318191a55e","volume":"36","author":"C Marra","year":"2009","unstructured":"Marra C, Ogilvie G, Gastonguay L, Colley L, Taylor D, Marra F. Patients with genital warts have a decreased quality of life. Sex Transm Dis. 2009;36:258\u201360.","journal-title":"Sex Transm Dis"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0691-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T12:45:55Z","timestamp":1569156355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0691-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0691-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"assertion":[{"value":"18 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by generous philanthropic contributions, including a contribution from the Lyda Hill Foundation to The University of Texas MD Anderson Cancer Center\u2019s Moon Shots Program, and was accomplished within the Oropharynx Program at The University of Texas MD Anderson Cancer Center and funded in part through the Stiefel Oropharyngeal Research Fund.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kristina R. Dahlstrom, Shuangshuang Fu, Wenyaw Chan, Zeena Shelal, Lois M. Ramondetta, and David R. Lairson have no conflict of interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The MarketScan claims data are available from Truven Health Analytics, now part of IBM Watson Health, with access fees subject to the level of research funding. Contact Dr Lairson for software code requests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}}]}}